SCHEMBL4166105

SCHEMBL4166105

Nc1ccccc1-c1nnc(Nc2ccc(C(F)(F)F)cc2)[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.40
MAPT P10636 4/20 0.40
ALDH1A1 P00352 3/20 0.40
GAA P10253 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 2/20 0.40
GFER P55789 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
RAB9A P51151 3/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
EPHX2 P34913 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
GSK3B P49841 1/20 0.36
TP53 P04637 1/20 0.36
TTBK1 Q5TCY1 1/20 0.36
TTBK2 Q6IQ55 1/20 0.36
NPC1 O15118 1/20 0.35
GLA P06280 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4166099 0.82 PARP1 (0.44) PTGS1RAB9ASMN1; SMN2NPC1MTOR
SCHEMBL28005785 0.81 SCN2A (0.48) MAPTGAAMEN1KMT2AGFER
SCHEMBL4521617 0.76 ALDH1A1 (0.40) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL19449706 0.73 ALOX5 (0.49) MAPTALDH1A1MEN1KMT2AGSK3B
SCHEMBL23554036 0.72 FADS1 (0.43) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL16740832 0.70 MEN1 (0.44) PTGS1MAPTALDH1A1GAAMEN1
SCHEMBL29824523 0.69 MAPT (0.68) PTGS1MAPTALDH1A1GAAMEN1
SCHEMBL15875869 0.69 MAPT (0.68) PTGS1MAPTALDH1A1GAAMEN1
SCHEMBL30554475 0.68 SYK (0.57) GSK3B
SCHEMBL25337325 0.68 SYK (0.57) GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 US disclosed
WO-2005004818-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TP53, MCL1, VHL PTGS1 835/4885MAPT 3261/4885ALDH1A1 535/4885
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents TP53, MCL1, VHL PTGS1 835/4885MAPT 3261/4885ALDH1A1 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.